Use of nicotinamide mononucleotide in preparation of drug for prevention or treatment on rtPA vascular complication

A single nucleotide, nicotinamide technology, applied in the field of medicine

Inactive Publication Date: 2018-01-05
SHANGHAI FENGJING BIOMEDICAL TECH CO LTD
View PDF5 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, in diseases such as acute myocardial infarction, pulmonary embolism, cerebral ischemia (ischemic stroke), venous thrombosis of the lower extremities, and thrombosis of the upper extremities, rtPA has the potential risk of inducing vascular complications, namely bleeding.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of nicotinamide mononucleotide in preparation of drug for prevention or treatment on rtPA vascular complication
  • Use of nicotinamide mononucleotide in preparation of drug for prevention or treatment on rtPA vascular complication
  • Use of nicotinamide mononucleotide in preparation of drug for prevention or treatment on rtPA vascular complication

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0035] Nicotinamide mononucleotide (NMN) antagonizes the blood extravasation induced by rtPA in the model of vascular complications induced by rtPA injection in mice.

[0036] In the present invention, the nicotinamide mononucleotide used is commercially available and purchased from Shenzhen Bangtai Bioengineering Co., Ltd. Its chemical structural formula is as follows:

[0037]

[0038] 1 Experimental method

[0039] rtPA is commercially available under the trade name Actilyse from Boehringer Ingelheim Pharmaceuticals, Germany. We used mice (ICR mice, weighing 25-30 g, Shanghai Slack Experimental Animal Co., Ltd.) to prepare the rtPA vascular complication model. The process is as follows: mice are anesthetized, and rtPA is injected from the tail vein (the dose is 9mg / kg). The hormone (representing blood) increases, that is, blood extravasation occurs. Tissue edema occurs after blood extravasation.

[0040] Mice were divided into three groups: control group, rtPA group...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a use of nicotinamide mononucleotide in preparation of a drug for prevention and/or treatment on rtPA vascular complication. rtPA is an important thrombolytic drug for treating acute myocardial infarction, pulmonary embolism and cerebral infarction, can easily produce untoward effects in clinical application and has obvious tendency of destroying a blood vessel barrier structure and inducing vascular complication such as bleeding. Based on a mouse vascular complication model caused by injection of rtPA, the protective effect of nicotinamide mononucleotide on rtPA-damaged blood vessels is researched. An experimental result shows that nicotinamide mononucleotide can significantly improve mouse blood extravasation caused by injection of rtPA, reduce tissue edema and increase expression of a blood vessel tight junction protein so that nicotinamide mononucleotide can resist rtPA-caused angiolysis and vascular complication.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to the application of nicotinamide mononucleotide in the preparation of drugs for the prevention or treatment of vascular complications of the currently commonly used clinical thrombolytic drug rtPA. Background technique [0002] The Chinese name of rtPA is recombinant tissue plasminogen activator, and its full English name is recombinant tissue plasminogen activator. Thrombolytic drugs. rtPA is a glycoprotein that activates plasminogen to become plasmin. When administered intravenously, the drug is active in the circulatory system only after binding to its fibrin, which has a high affinity for fibrin. When combined with fibrin, this product is activated to induce plasminogen to become plasmin, so as to dissolve the fibrin in the blood clot and achieve the purpose of dissolving thrombus. [0003] Whether it is in acute myocardial infarction, pulmonary embolism, or in diseases su...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/706A61K38/49A61P7/02A61P7/04A61P7/10A61P9/14
Inventor 缪朝玉王培
Owner SHANGHAI FENGJING BIOMEDICAL TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap